How to appeal a Premera Blue Cross immune globulin (ivig/scig) for pidd denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Premera Blue Cross-specific note: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.

What Premera Blue Cross's policy requires for immune globulin (ivig/scig) for pidd

Cited policy: BCBS Federal Employee Program / BCBSA Medical Policy on Immune Globulin Therapy

Route conversion (IVIG → SCIG / fSCIG) requires documented clinical indication: IVIG adverse reaction, venous access difficulty, patient preference with stable disease, or steady-state trough optimization. Continued PIDD diagnosis criteria.

How Premera Blue Cross denies immune globulin (ivig/scig) for pidd — and how to counter it

Where Premera Blue Cross pushes back: 1) Patient stable on IVIG — no reason to change; 2) Brand-specific (Privigen vs Gamunex) swap not justified.

Counter-arguments that hold up: Cite specific IVIG reaction (headache / aseptic meningitis / hemolysis / TE / IgA-anti-IgA anaphylaxis) with date, premed-failure documentation. Berger 2008 SCIG meta — fewer systemic AEs. Orange 2010 trough-pneumonia data — SCIG steadier troughs reduce breakthrough infections. Mahlaoui QoL — improved treatment-satisfaction. Excipient differences (proline / glycine / sorbitol / maltose) matter — Bonilla 2015 SS supports product-specific selection when reactions documented. Line-related complications (DVT, CLABSI) justify route change.

What Premera Blue Cross typically denies for immune globulin (ivig/scig) for pidd

Across Premera Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For immune globulin (ivig/scig) for pidd, expect:

• WA-specific mental health parity violations
• Step therapy via Express Scripts
• Out-of-network reductions
• Specialty drug prior auth

Treatments most often denied in this category

These are the immune globulin (ivig/scig) for pidd treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Privigen (IVIG)
• Gamunex-C (IVIG)
• Octagam (IVIG)
• Gammagard Liquid (IVIG)
• Flebogamma DIF (IVIG)
• Bivigam (IVIG)

How to submit the appeal to Premera Blue Cross

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Premera Blue Cross cited in the denial.
3. File the appeal through Premera Blue Cross's portal (members: https://www.premera.com ; providers: https://www.premera.com/wa/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In WA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Premera Blue Cross's prior-authorization criteria by drug: Premera Blue Cross PA criteria on ApprovalHelp.